|
AU6044699A
(en)
*
|
1998-09-17 |
2000-04-03 |
Akesis Pharmaceuticals, Inc. |
Compositions and methods for treatment of glucose metabolism disorders
|
|
US6376549B1
(en)
*
|
1998-09-17 |
2002-04-23 |
Akesis Pharmaceuticals, Inc. |
Metforimin-containing compositions for the treatment of diabetes
|
|
DE19940130A1
(de)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
|
WO2001034594A1
(en)
*
|
1999-11-12 |
2001-05-17 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
|
|
US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
|
KR20020063260A
(ko)
*
|
1999-12-23 |
2002-08-01 |
노파르티스 아게 |
당 대사 장애를 치료하기 위한 혈당강하제의 용도
|
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
|
JP2003520226A
(ja)
*
|
2000-01-21 |
2003-07-02 |
ノバルティス アクチエンゲゼルシャフト |
ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
|
|
JP2003520849A
(ja)
*
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
|
WO2002002560A2
(en)
|
2000-07-04 |
2002-01-10 |
Novo Nordisk A/S |
Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
|
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
|
US20060089389A1
(en)
*
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
|
DK1326630T3
(da)
|
2000-09-18 |
2008-09-15 |
Sanos Bioscience As |
Anvendelse af GLP-2-peptider
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
NZ524974A
(en)
|
2000-10-06 |
2005-10-28 |
Tanabe Seiyaku Co |
Aliphatic nitrogen-containing 5-membered ring compound
|
|
TWI243162B
(en)
*
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
|
UA74023C2
(en)
*
|
2000-11-10 |
2005-10-17 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
|
WO2002051836A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
|
US7253172B2
(en)
|
2001-06-20 |
2007-08-07 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
WO2003000180A2
(en)
|
2001-06-20 |
2003-01-03 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
CN1990468A
(zh)
|
2001-06-27 |
2007-07-04 |
史密丝克莱恩比彻姆公司 |
作为二肽酶抑制剂的氟代吡咯烷
|
|
ATE370943T1
(de)
*
|
2001-06-27 |
2007-09-15 |
Smithkline Beecham Corp |
Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
|
|
JP4300108B2
(ja)
|
2001-06-27 |
2009-07-22 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
|
|
US6709651B2
(en)
*
|
2001-07-03 |
2004-03-23 |
B.M.R.A. Corporation B.V. |
Treatment of substance P-related disorders
|
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
|
JP2005507261A
(ja)
*
|
2001-10-31 |
2005-03-17 |
ノバルティス アクチエンゲゼルシャフト |
Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法
|
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
|
US20030135663A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Sun Microsystems, Inc. |
Method, system, and program for including device parameters from a device driver in a configuration file
|
|
BR0307665A
(pt)
|
2002-02-13 |
2005-01-04 |
Hoffmann La Roche |
Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
|
|
WO2003068748A1
(en)
|
2002-02-13 |
2003-08-21 |
F. Hoffmann-La Roche Ag |
Novel pyridine- and quinoline-derivatives
|
|
EP1338595B1
(en)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Xanthine derivatives as DPP-IV inhibitors
|
|
AU2003225916A1
(en)
*
|
2002-03-25 |
2003-10-13 |
Merck & Co., Inc. |
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
CN100402026C
(zh)
*
|
2002-06-03 |
2008-07-16 |
诺瓦提斯公司 |
取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途
|
|
US6710040B1
(en)
*
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
|
JP2004026678A
(ja)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
２型糖尿病治療剤
|
|
WO2004007446A1
(ja)
*
|
2002-07-10 |
2004-01-22 |
Yamanouchi Pharmaceutical Co., Ltd. |
新規なアゼチジン誘導体又はその塩
|
|
WO2004007468A1
(en)
*
|
2002-07-15 |
2004-01-22 |
Merck & Co., Inc. |
Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
|
|
TW200401635A
(en)
*
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
NZ538567A
(en)
*
|
2002-09-19 |
2007-04-27 |
Abbott Lab |
Pyrrolidine-2-carbonitrile derivatives and their pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
|
CA2499586A1
(en)
|
2002-10-07 |
2004-04-22 |
Merck & Co., Inc. |
Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
|
|
MXPA05004063A
(es)
|
2002-10-18 |
2005-06-08 |
Merck & Co Inc |
Inhibidores de la beta-amino heterociclico dipeptidil peptidasa para el tratamiento o prevencion de diabetes.
|
|
MXPA05004890A
(es)
|
2002-11-07 |
2005-07-22 |
Merck & Co Inc |
Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
|
|
AU2003297564A1
(en)
*
|
2002-12-04 |
2004-06-23 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
WO2004058266A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
BRPI0406761A
(pt)
|
2003-01-14 |
2005-12-20 |
Arena Pharm Inc |
Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
|
|
WO2004064778A2
(en)
|
2003-01-17 |
2004-08-05 |
Merck & Co. Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
WO2004069162A2
(en)
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
KR20050122220A
(ko)
|
2003-03-25 |
2005-12-28 |
다케다 샌디에고, 인코포레이티드 |
디펩티딜 펩티다제 억제제
|
|
PE20050021A1
(es)
*
|
2003-04-16 |
2005-03-15 |
Novartis Ag |
Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
|
|
GB0308854D0
(en)
*
|
2003-04-16 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
|
US7560455B2
(en)
|
2003-05-14 |
2009-07-14 |
Merck & Co., Inc. |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
AU2004247068A1
(en)
*
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
|
EP1638950A4
(en)
|
2003-06-17 |
2010-06-30 |
Merck Sharp & Dohme |
CYCLOHEXYLGLYCIN DERIVATIVES AS DIPEPTIDYLPEPTIDASEINHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES
|
|
ES2327740T3
(es)
|
2003-06-20 |
2009-11-03 |
F. Hoffmann-La Roche Ag |
Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv.
|
|
HRP20110018T1
(hr)
|
2003-06-20 |
2011-02-28 |
F. Hoffmann - La Roche Ag |
Derivati pirido(2,1-a)-izokinolina kao inhibitori dpp-iv
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
WO2005011581A2
(en)
|
2003-07-31 |
2005-02-10 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7579357B2
(en)
|
2003-08-13 |
2009-08-25 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
WO2005026148A1
(en)
|
2003-09-08 |
2005-03-24 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
TW200530157A
(en)
*
|
2003-09-09 |
2005-09-16 |
Japan Tobacco Inc |
Dipeptidyl peptidase iv inhibitor
|
|
WO2005033099A2
(en)
*
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
|
ZA200603165B
(en)
*
|
2003-11-03 |
2007-07-25 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
|
JP2007510651A
(ja)
*
|
2003-11-04 |
2007-04-26 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体
|
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
DK1689757T3
(en)
*
|
2003-11-12 |
2014-12-08 |
Sino Med Internat Alliance Inc |
HETEROCYCLIC DRY ACID COMPOUNDS
|
|
RU2385723C2
(ru)
*
|
2003-11-17 |
2010-04-10 |
Новартис Аг |
Применение ингибиторов дипептидилпептидазы iv
|
|
KR20170104639A
(ko)
*
|
2003-11-17 |
2017-09-15 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
|
HRP20211766T1
(hr)
|
2004-01-20 |
2022-02-18 |
Novartis Ag |
Formulacija i postupak izravne kompresije
|
|
RS52163B
(sr)
*
|
2004-02-05 |
2012-08-31 |
Kyorin Pharmaceutical Co. Ltd. |
Derivati bicikloestra
|
|
CN1922139B
(zh)
*
|
2004-02-18 |
2010-12-29 |
杏林制药株式会社 |
双环酰胺衍生物
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CA2555399A1
(en)
*
|
2004-02-20 |
2005-09-01 |
Novartis Ag |
Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
|
|
CA2557275C
(en)
*
|
2004-02-27 |
2012-06-05 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
|
CN1942186B
(zh)
*
|
2004-03-09 |
2010-10-06 |
国家卫生研究院 |
吡咯烷化合物
|
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
MXPA06010571A
(es)
|
2004-03-15 |
2007-02-16 |
Takeda Pharmaceutical |
Inhibidores de dipeptidil peptidasa.
|
|
US7741082B2
(en)
*
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
|
TW200604167A
(en)
*
|
2004-04-27 |
2006-02-01 |
Astellas Pharma Inc |
Pyrrolidine derivatives
|
|
WO2005108382A1
(en)
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
CA2564884A1
(en)
|
2004-05-18 |
2005-12-08 |
Merck & Co., Inc. |
Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US7687638B2
(en)
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
US7935723B2
(en)
*
|
2004-06-04 |
2011-05-03 |
Novartis Pharma Ag |
Use of organic compounds
|
|
US7786163B2
(en)
|
2004-07-12 |
2010-08-31 |
Forest Laboratories Holdings Limited (BM) |
Constrained cyano compounds
|
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
|
US7842707B2
(en)
|
2004-07-23 |
2010-11-30 |
Nuada, Llc |
Peptidase inhibitors
|
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
|
PE20060652A1
(es)
*
|
2004-08-27 |
2006-08-11 |
Novartis Ag |
Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion
|
|
AU2005293266B2
(en)
|
2004-10-12 |
2011-09-29 |
Glenmark Pharmaceuticals S.A. |
Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
|
|
CN101035522B
(zh)
*
|
2004-10-25 |
2011-12-07 |
诺瓦提斯公司 |
Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
|
KR100904829B1
(ko)
|
2004-12-20 |
2009-06-25 |
에프. 호프만-라 로슈 아게 |
4-아미노피페리딘 유도체
|
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
GT200600008A
(es)
*
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
|
WO2006090244A1
(en)
*
|
2005-02-22 |
2006-08-31 |
Glenmark Pharmaceuticals S.A. |
New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
|
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
|
BRPI0608469A2
(pt)
*
|
2005-04-22 |
2010-01-05 |
Alantos Pharmaceuticals Holding Inc |
inibidores de dipeptidil peptidase-iv
|
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
|
CA2610022A1
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
|
US20090149504A1
(en)
*
|
2005-06-17 |
2009-06-11 |
Aurigene Discovery Technologies Limited |
Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors
|
|
CN101222919A
(zh)
*
|
2005-07-12 |
2008-07-16 |
诺瓦提斯公司 |
Dpp-ⅳ抑制剂与大麻素受体-1（cb1）拮抗物的组合
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
KR20080031936A
(ko)
*
|
2005-08-04 |
2008-04-11 |
노파르티스 아게 |
빌다글립틴의 염
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
PL1942898T5
(pl)
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
|
|
WO2007035629A2
(en)
|
2005-09-16 |
2007-03-29 |
Takeda Pharmaceutical Company Limited |
Process for the preparation of pyrimidinedione derivatives
|
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
|
CA2625150A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Waratah Pharmaceuticals, Inc. |
Combined use of dpp-iv inhibitors and gastrin compounds
|
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
|
CA2635399A1
(en)
*
|
2006-01-06 |
2007-10-25 |
Novartis Ag |
Use.of vildagliptin for the treatment of diabetes
|
|
CA2645154C
(en)
|
2006-03-08 |
2011-11-29 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
NZ571319A
(en)
*
|
2006-04-03 |
2011-05-27 |
Matrix Lab Ltd |
Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them
|
|
WO2007113634A1
(en)
*
|
2006-04-03 |
2007-10-11 |
Matrix Laboratories Ltd. |
Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them
|
|
ATE487940T1
(de)
|
2006-04-11 |
2010-11-15 |
Arena Pharm Inc |
Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
SG174054A1
(en)
|
2006-05-04 |
2011-09-29 |
Boehringer Ingelheim Int |
Polymorphs
|
|
EP2636680A3
(en)
|
2006-05-26 |
2013-12-11 |
Amylin Pharmaceuticals, LLC |
Composition and methods for treatment of congestive heart failure
|
|
AU2007293885A1
(en)
|
2006-09-07 |
2008-03-13 |
Takeda Gmbh |
Combination treatment for diabetes mellitus
|
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
|
AR062760A1
(es)
*
|
2006-09-13 |
2008-12-03 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidilpetidasa
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
US20080167479A1
(en)
*
|
2007-01-10 |
2008-07-10 |
Medichem, S.A. |
Process for preparing vildagliptin
|
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
|
JPWO2008114857A1
(ja)
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
|
JP5616630B2
(ja)
|
2007-04-03 |
2014-10-29 |
田辺三菱製薬株式会社 |
ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
|
|
DE102007022007A1
(de)
*
|
2007-05-08 |
2008-11-13 |
Schebo Biotech Ag |
Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
|
|
PL2152663T3
(pl)
|
2007-06-04 |
2014-09-30 |
Ben Gurion Univ Of The Negev Research And Development Authority |
Związki triarylowe oraz kompozycje zawierające te związki
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
WO2009024542A2
(en)
*
|
2007-08-17 |
2009-02-26 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
|
WO2009037719A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Lupin Limited |
Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
|
|
US20090082420A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched vildagliptin
|
|
US8598314B2
(en)
*
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
|
EP2247602B1
(en)
*
|
2007-11-30 |
2013-04-03 |
Novartis AG |
Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
|
|
WO2009074829A1
(en)
|
2007-12-12 |
2009-06-18 |
Astrazeneca Ab |
Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
|
|
JP5358585B2
(ja)
|
2007-12-21 |
2013-12-04 |
エルジー ライフ サイエンス リミテッド |
ジペプチジルペプチダーゼ−ｉｖ阻害化合物、同化合物を製造する方法、及び活性剤として同化合物を含む医薬組成物
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
|
WO2009155309A1
(en)
*
|
2008-06-19 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Substituted cyanopyrrolidine derivatives
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
EP2322499A4
(en)
*
|
2008-08-07 |
2011-12-21 |
Kyorin Seiyaku Kk |
PROCESS FOR PREPARING A BICYCLO [2,2,2] OCTYLAMINE DERIVATIVE
|
|
JPWO2010018866A1
(ja)
*
|
2008-08-14 |
2012-01-26 |
杏林製薬株式会社 |
安定化された医薬組成物
|
|
CN102123704B
(zh)
|
2008-08-15 |
2014-02-12 |
勃林格殷格翰国际有限公司 |
用于治疗fab-相关疾病的嘌呤衍生物
|
|
CZ2008512A3
(cs)
*
|
2008-08-26 |
2010-03-10 |
Zentiva, A. S |
Zpusob prípravy vysoce cistého vildagliptinu
|
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
|
CN102850330B
(zh)
*
|
2008-09-23 |
2014-10-15 |
成都地奥制药集团有限公司 |
经溴代的制备n取代的吡咯烷衍生物的方法
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
|
EA022310B1
(ru)
|
2008-12-23 |
2015-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Солевые формы органического соединения
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
EP2376447B1
(en)
|
2009-01-09 |
2017-08-09 |
Orchid Pharma Limited |
Dipeptidyl peptidase iv inhibitors
|
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
|
CN117547538A
(zh)
|
2009-02-13 |
2024-02-13 |
勃林格殷格翰国际有限公司 |
包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
|
|
KR20120003906A
(ko)
|
2009-03-27 |
2012-01-11 |
교린 세이야꾸 가부시키 가이샤 |
염기성 첨가제를 함유하는 매트릭스형 서방성 제제
|
|
EA201190235A1
(ru)
|
2009-05-07 |
2012-05-30 |
Астразенека Аб |
Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
|
|
WO2010130796A1
(en)
|
2009-05-15 |
2010-11-18 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors
|
|
MX2011012199A
(es)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
|
|
JP5420761B2
(ja)
|
2009-05-28 |
2014-02-19 |
ノバルティス アーゲー |
ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
|
|
KR20120041702A
(ko)
|
2009-05-28 |
2012-05-02 |
노파르티스 아게 |
네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
|
|
US8748457B2
(en)
|
2009-06-18 |
2014-06-10 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
|
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
EA034049B1
(ru)
*
|
2009-07-31 |
2019-12-23 |
КРКА, д.д., НОВО МЕСТО |
Гранулят, включающий вилдаглиптин, способ его получения и фармацевтическая композиция
|
|
IN2012DN00721A
(enExample)
|
2009-09-02 |
2015-06-19 |
Merck Sharp & Dohme |
|
|
NZ598294A
(en)
|
2009-09-03 |
2013-07-26 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
EA201200486A1
(ru)
|
2009-09-15 |
2012-08-30 |
Серулин Фарма Инк. |
Лечение онкологических заболеваний
|
|
EP2295083A1
(de)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
|
|
HUP0900638A2
(en)
|
2009-10-07 |
2011-05-30 |
Egyt Gyogyszervegyeszeti Gyar |
Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
|
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物
|
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
|
ES2663351T3
(es)
|
2009-11-17 |
2018-04-12 |
Novartis Ag |
Derivados de aril-piridina como inhibidores de la aldosterona sintasa
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
CN102781237A
(zh)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
|
WO2011064376A1
(en)
|
2009-11-30 |
2011-06-03 |
Novartis Ag |
Imidazole derivatives as aldosterone synthase inhibitors
|
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
|
JP5686413B2
(ja)
|
2009-12-22 |
2015-03-18 |
塩野義製薬株式会社 |
アダマンタンアミン誘導体
|
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
EP2538783B1
(en)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
CN101798270B
(zh)
*
|
2010-02-25 |
2013-04-17 |
东华大学 |
一种3-氨基-1-金刚烷醇的制备方法
|
|
US20130109703A1
(en)
|
2010-03-18 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
|
|
JP2013523819A
(ja)
|
2010-04-06 |
2013-06-17 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
|
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
EP2571876B1
(en)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
|
CN102260265B
(zh)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
|
|
CN101870671B
(zh)
*
|
2010-06-11 |
2012-06-27 |
漆又毛 |
金刚烷基吡咯烷衍生物及制备和应用
|
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
|
IT1400714B1
(it)
|
2010-07-06 |
2013-06-28 |
Chemelectiva S R L |
Processo ed intermedi per la preparazione di un principio attivo.
|
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
|
CN103209957A
(zh)
*
|
2010-08-09 |
2013-07-17 |
盐野义制药株式会社 |
氨基金刚烷氨基甲酸酯衍生物的制备方法
|
|
HU231050B1
(hu)
|
2010-08-19 |
2020-02-28 |
Egis Gyógyszergyár Nyrt. |
Eljárás gyógyszerhatóanyag előállítására
|
|
SG188548A1
(en)
|
2010-09-22 |
2013-04-30 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
|
EP2468268B1
(en)
|
2010-12-21 |
2017-12-13 |
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Combination composition of vildagliptin and gliclazide
|
|
TR201101809A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Vildagliptin ve glimepirid kombinasyonları.
|
|
TR201107482A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San.Ve Ti̇c.A.Ş. |
Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
|
|
TR201010683A1
(tr)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San. Ve Ti̇c. A.Ş. |
Vildagliptin formülasyonları.
|
|
US10017470B2
(en)
|
2011-01-31 |
2018-07-10 |
Cadila Healthcare Limited |
Treatment for lipodystrophy
|
|
AU2012223232B2
(en)
|
2011-03-02 |
2017-05-25 |
Bioenergenix |
Heterocyclic compounds for the inhibition of PASK
|
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
WO2013006526A2
(en)
|
2011-07-05 |
2013-01-10 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
EA201490556A1
(ru)
|
2011-09-07 |
2014-08-29 |
Сановел Илач Санайи Ве Тиджарет Аноним Ширкети |
Составы ингибитора дпп-4
|
|
EP2572704A1
(en)
|
2011-09-22 |
2013-03-27 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally-Disintegrating Formulations of Vildagliptin
|
|
PL2578208T3
(pl)
|
2011-10-06 |
2014-10-31 |
Sanovel Ilac Sanayi Ve Ticaret As |
Stałe formulacje dawkowane inhibitora DPP-IV
|
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
ITMI20112224A1
(it)
|
2011-12-06 |
2013-06-07 |
Chemelectiva S R L |
Nuovo processo ed intermedi per la sintesi di vildagliptin
|
|
CN102491928A
(zh)
*
|
2011-12-13 |
2012-06-13 |
临海天宇药业有限公司 |
一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法
|
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
CN102617434B
(zh)
*
|
2012-03-29 |
2014-07-23 |
中国科学院上海有机化学研究所 |
一锅法制备维达列汀
|
|
IN2012MU01383A
(enExample)
|
2012-05-04 |
2014-02-28 |
|
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
EP2874622A4
(en)
|
2012-07-23 |
2015-12-30 |
Merck Sharp & Dohme |
TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
|
|
WO2014020462A1
(en)
*
|
2012-08-01 |
2014-02-06 |
Alembic Pharmaceuticals Limited |
Improved process for preparation of vildagliptin intermediate
|
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
|
CN103922986B
(zh)
*
|
2013-01-16 |
2017-02-15 |
上海彩迩文生化科技有限公司 |
维大列汀及其类似物、中间体及其制备方法和应用
|
|
WO2014126979A1
(en)
|
2013-02-14 |
2014-08-21 |
Novartis Ag |
Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
|
|
EA201592020A1
(ru)
|
2013-04-22 |
2016-05-31 |
Кадила Хелзкэр Лимитед |
Новая композиция для неалкогольной жировой болезни печени (нажбп)
|
|
PH12015502667B1
(en)
|
2013-05-30 |
2023-10-18 |
Zydus Lifesciences Ltd |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
|
CN103304502B
(zh)
*
|
2013-06-02 |
2015-03-04 |
张远强 |
一类抗糖尿病化合物、其制备方法和用途
|
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
|
CA2918074A1
(en)
|
2013-07-25 |
2015-01-29 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure
|
|
IN2013MU02470A
(enExample)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
|
CA2918077A1
(en)
|
2013-07-25 |
2015-01-29 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
|
IN2013MU02905A
(enExample)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
|
CR20160207A
(es)
|
2013-11-05 |
2016-08-10 |
Ben Gurion Univ Of The Negev Res And Dev Authority |
Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
|
|
CN103641761A
(zh)
*
|
2013-11-22 |
2014-03-19 |
沈阳化工大学 |
一种维格利汀的制备方法
|
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｄｐｐ−４阻害薬の医学的使用
|
|
US20170014380A1
(en)
|
2014-03-06 |
2017-01-19 |
Sanovell IIac Sanayi Ve Ticaret Anonim Sirketi |
Vildagliptin Formulation Process Under Inert Gas Atmosphere
|
|
CN103992257B
(zh)
*
|
2014-05-16 |
2016-03-30 |
苏州天马精细化学品股份有限公司 |
一种维格列汀粗品的纯化方法
|
|
CN105439873A
(zh)
*
|
2014-08-20 |
2016-03-30 |
天津药物研究院 |
3-羟基-1-金刚烷胺的制备方法
|
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
|
CN105884669B
(zh)
*
|
2014-09-15 |
2020-05-15 |
深圳翰宇药业股份有限公司 |
制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法
|
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
CN104529857B
(zh)
*
|
2015-01-13 |
2016-03-30 |
佛山市赛维斯医药科技有限公司 |
卤代金刚烷酰胺类衍生物、其制备方法和用途
|
|
AU2016209968B2
(en)
|
2015-01-23 |
2018-11-29 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
|
WO2016144862A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
CN104761456B
(zh)
*
|
2015-03-10 |
2020-04-10 |
上海威智医药科技有限公司 |
3-氨基-1-金刚烷醇的制备方法
|
|
CN104817482B
(zh)
*
|
2015-03-17 |
2017-05-10 |
宁波百思佳医药科技有限公司 |
2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
|
|
CA3002551A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
|
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
|
RU2628573C2
(ru)
*
|
2015-11-27 |
2017-08-21 |
Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" |
Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа
|
|
BR112018013195A2
(pt)
|
2015-12-28 |
2018-12-11 |
Wockhardt Ltd |
composição farmacêutica osmótica oral de vildagliptina
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
DE102016116130A1
(de)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Verfahren zur Herstellung chiraler Aminonitrile
|
|
ES2946233T3
(es)
|
2016-09-16 |
2023-07-14 |
Galenicum Health S L U |
Composiciones farmacéuticas de vildagliptina
|
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
|
JP6840853B2
(ja)
|
2016-12-09 |
2021-03-10 |
カディラ・ヘルスケア・リミテッド |
原発性胆汁性胆管炎の治療
|
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
|
KR20200036808A
(ko)
|
2017-04-03 |
2020-04-07 |
코히러스 바이오사이언시스, 인크. |
진행성 핵상 마비 치료를 위한 PPARγ 작용제
|
|
GR1009406B
(el)
|
2017-10-03 |
2018-11-26 |
Φαρματεν Αβεε |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
|
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
|
KR102622198B1
(ko)
|
2018-03-30 |
2024-01-09 |
한미약품 주식회사 |
빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
GR1009644B
(el)
|
2018-09-25 |
2019-11-12 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
|
|
WO2020110011A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
|
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
|
US20230089867A1
(en)
|
2018-11-27 |
2023-03-23 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
|
JP7461735B2
(ja)
*
|
2019-12-02 |
2024-04-04 |
日本ジェネリック株式会社 |
ビルダグリプチン含有錠剤
|
|
CN113527167B
(zh)
*
|
2020-04-14 |
2024-01-19 |
威智医药股份有限公司 |
一种维格列汀的生产方法
|
|
WO2021234430A1
(en)
|
2020-05-17 |
2021-11-25 |
Lotus International Pte. Ltd. |
Modified release dosage form comprising vildagliptin and process for manufacturing the same
|
|
WO2022003405A1
(en)
|
2020-07-03 |
2022-01-06 |
Savoi Guilherme |
One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same
|
|
JP2023536346A
(ja)
|
2020-08-05 |
2023-08-24 |
エリプシーズ ファーマ リミテッド |
シクロデキストリン含有ポリマートポイソメラーゼ阻害剤コンジュゲートおよびｐａｒｐ阻害剤を用いた癌の処置
|
|
MX2023008275A
(es)
*
|
2021-01-21 |
2023-07-19 |
Scripps Research Inst |
Reguladores de moleculas peque?as de la proliferacion de celulas alveolares tipo 2 para el tratamiento de enfermedades pulmonares.
|
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
|
WO2024241229A1
(en)
|
2023-05-24 |
2024-11-28 |
Novartis Ag |
Naphthyridinone derivatives for the treatment of a disease or disorder
|